Home › Research › Tau biomarkers
Outcome associations of CSF total tau in suspected non-Alzheimer pathophysiology
Briel N, Borsi M, Schreiner SJ, Schneider T, Loosli SV, Togni C, Carta MC, Loosli J et al.. Journal of neurology, 2026-04-30
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction Cognitively impaired patients with negative biomarkers of amyloidosis but with neurochemical evidence of Tau pathophysiology or neurodegeneration or both are classified as "suspected non-Alzheimer pathophysiology" (SNAP), according to the 2018 research framework for a biological definition of Alzheimer's disease (AD). The SNAP concept remains incompletely characterized, and associations of amyloid and tau biomarkers with survival outcomes in the SNAP context remain unclear. Methods We conducted a retrospective study in patients with a SNAP biomarker constellation, recruited from two tertiary centers between 2019 and 2024.
What this study adds
Evidence grade: Low
The record lists 99 participants. This retrospective study looked at survival outcomes in patients classified as having suspected non-Alzheimer pathophysiology, based on negative amyloid biomarkers with evidence of tau pathophysiology or neurodegeneration. Reported effect size: AUC = 0.83; AUC = 0.82.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Briel, N., Borsi, M., Schreiner, S. J., Schneider, T., Loosli, S. V., Togni, C., et al. (2026). Outcome associations of CSF total tau in suspected non-Alzheimer pathophysiology. Journal of neurology. https://doi.org/10.1007/s00415-026-13841-x
Vancouver
Briel N, Borsi M, Schreiner SJ, Schneider T, Loosli SV, Togni C, et al. Outcome associations of CSF total tau in suspected non-Alzheimer pathophysiology. Journal of neurology. 2026. doi:10.1007/s00415-026-13841-x. PMID: 42060129.
BibTeX
@article{briel2026-42060129,
author = {Briel, N. and Borsi, M. and Schreiner, S. J. and Schneider, T. and Loosli, S. V. and Togni, C. and Carta, M. C. and Loosli, J. and others},
title = {{Outcome associations of CSF total tau in suspected non-Alzheimer pathophysiology}},
journal = {Journal of neurology},
year = {2026},
doi = {10.1007/s00415-026-13841-x},
pmid = {42060129},
url = {https://doi.org/10.1007/s00415-026-13841-x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The SNAP concept remains incompletely characterized, and associations of amyloid and tau biomarkers with survival outcomes in the SNAP context remain unclear.
- Methods We conducted a retrospective study in patients with a SNAP biomarker constellation, recruited from two tertiary centers between 2019 and 2024.
- We extracted clinical demographic variables, biomarker results, and survival times to all-cause-mortality or last seen from electronic health records.
- SNAP patients were defined based on normal cerebrospinal fluid (CSF) levels of amyloid-β 1-42 (Aβ 42 ) and a normal Aβ 42 /Aβ 40 ratio, and abnormal levels of phospho-Tau-181 (pTau) and/or total Tau (tTau), as measured with the Lumipulse G chemiluminescence assay.
Why it matters
This retrospective study looked at survival outcomes in patients classified as having suspected non-Alzheimer pathophysiology, based on negative amyloid biomarkers with evidence of tau pathophysiology or neurodegeneration. It is about characterizing this group and its outcomes, not about any treatment, cure or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants99
- Effect sizeAUC = 0.83; AUC = 0.82
- Evidence strengthLow
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 40 of the 96 points we could judge it on, which is 42 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of neurology) |
| Journal's citation record | 2 / 4 | Journal of Neurology: journal h-index 208 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 1 / 4 | 99 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Hans H Jung holds only 1 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 3 / 3 | Centre National de la Recherche Scientifique: institution h-index 2,511 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 12 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42060129) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 40 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 40 of the 96 points we could judge it on is 42 out of 100. |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Tau biomarkers from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.